$ALLO
Allogene Therapeutics, Inc. Stock $allo

$allo Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-K Financial Statement

#000173728721000009 Filed on February 25, 2021

Income Statement

Concept	2020 Q4	2020	2019 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$17.13M	$65.26M	$15.21M
YoY Change	12.62%	13.55%	14.02%
% of Gross Profit
Research & Development	$52.23M	$193.0M	$49.76M
YoY Change	4.96%	33.52%	192.71%
% of Gross Profit
Depreciation & Amortization	$1.850M	$7.400M	$1.850M
YoY Change	0.0%	60.87%	236.36%
% of Gross Profit
Operating Expenses	$69.36M	$258.2M	$64.98M
YoY Change	6.74%	27.84%	114.17%
Operating Profit		-$258.2M	-$64.58M
YoY Change		27.84%	95.41%
Interest Expense	$1.560M	$0.00	$3.660M
YoY Change	-57.38%		-13.27%
% of Operating Profit
Other Income/Expense, Net	-$770.0K	$8.022M	-$270.0K
YoY Change	185.19%	-53.04%
Pretax Income	-$68.57M	-$250.2M	-$61.19M
YoY Change	12.06%	35.31%	99.77%
Income Tax	$0.00	$0.00	-$160.0K
% Of Pretax Income
Net Earnings	-$68.57M	-$250.2M	-$61.03M
YoY Change	12.35%	35.55%	100.04%
Net Earnings / Revenue
Basic Earnings Per Share		-$2.08
Diluted Earnings Per Share	-$528.3K	-$2.08	-$582.1K
COMMON SHARES
Basic Shares Outstanding	140.3M shares	120.4M shares	121.9M shares
Diluted Shares Outstanding		120.4M shares

Balance Sheet

Concept	2020 Q4	2020	2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$827.9M	$827.9M	$530.5M
YoY Change	56.05%	56.06%	15.49%
Cash & Equivalents	$183.4M	$183.4M	$175.1M
Short-Term Investments	$644.6M	$644.6M	$355.4M
Other Short-Term Assets	$17.20M	$14.40M	$11.60M
YoY Change	48.28%	24.14%	34.88%
Inventory
Prepaid Expenses
Receivables		$2.800M
Other Receivables		$0.00
Total Short-Term Assets	$845.1M	$845.1M	$544.6M
YoY Change	55.19%	55.18%	16.37%
LONG-TERM ASSETS
Property, Plant & Equipment	$118.8M	$160.1M	$56.45M
YoY Change	110.53%	58.67%	556.77%
Goodwill
YoY Change
Intangibles	$0.00		$151.0K
YoY Change	-100.0%		-79.97%
Long-Term Investments	$207.9M	$207.9M	$63.20M
YoY Change	228.96%	228.96%	-75.88%
Other Assets	$5.169M	$14.60M	$4.618M
YoY Change	11.93%	64.04%	1792.62%
Total Long-Term Assets	$382.7M	$382.7M	$173.2M
YoY Change	120.92%	120.96%	-43.37%
TOTAL ASSETS
Total Short-Term Assets	$845.1M	$845.1M	$544.6M
Total Long-Term Assets	$382.7M	$382.7M	$173.2M
Total Assets	$1.228B	$1.228B	$717.8M
YoY Change	71.05%	71.05%	-7.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$10.39M	$10.40M	$9.250M
YoY Change	12.32%	11.83%	-25.03%
Accrued Expenses	$44.90M	$44.90M	$23.80M
YoY Change	88.66%	88.66%	39.18%
Deferred Revenue	$38.99M		$0.00
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$94.32M	$94.30M	$33.08M
YoY Change	185.14%	184.89%	12.29%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$3.083M	$53.90M	$4.351M
YoY Change	-29.14%	-3.23%	-35.79%
Total Long-Term Liabilities	$3.083M	$53.90M	$4.351M
YoY Change	-29.14%	-3.23%	-35.79%
TOTAL LIABILITIES
Total Short-Term Liabilities	$94.32M	$94.30M	$33.08M
Total Long-Term Liabilities	$3.083M	$53.90M	$4.351M
Total Liabilities	$148.2M	$148.2M	$88.78M
YoY Change	66.94%	66.89%	25.59%
SHAREHOLDERS EQUITY
Retained Earnings	-$646.3M		-$396.1M
YoY Change	63.17%		87.27%
Common Stock	$1.726B		$1.024B
YoY Change	68.52%		11.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.080B	$1.080B	$629.0M
YoY Change
Total Liabilities & Shareholders Equity	$1.228B	$1.228B	$717.8M
YoY Change	71.05%	71.05%	-7.24%

Cashflow Statement

Concept	2020 Q4	2020	2019 Q4
OPERATING ACTIVITIES
Net Income	-$68.57M	-$250.2M	-$61.03M
YoY Change	12.35%	35.55%	100.04%
Depreciation, Depletion And Amortization	$1.850M	$7.400M	$1.850M
YoY Change	0.0%	60.87%	236.36%
Cash From Operating Activities	-$9.970M	-$115.1M	-$50.27M
YoY Change	-80.17%	-16.2%	134.03%
INVESTING ACTIVITIES
Capital Expenditures	-$17.41M	$65.96M	-$14.11M
YoY Change	23.39%	29.86%	968.94%
Acquisitions
YoY Change
Other Investing Activities	$39.61M	-$439.2M	$22.05M
YoY Change	79.64%	-304.38%	-107.07%
Cash From Investing Activities	$22.21M	-$505.1M	$7.920M
YoY Change	180.43%	-407.84%	-102.53%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$595.7M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	12.98M	$633.6M	56.47M
YoY Change	-77.01%	974.61%	-83.61%
NET CHANGE
Cash From Operating Activities	-9.970M	-$115.1M	-50.27M
Cash From Investing Activities	22.21M	-$505.1M	7.920M
Cash From Financing Activities	12.98M	$633.6M	56.47M
Net Change In Cash	25.22M	$13.38M	14.12M
YoY Change	78.61%	-84.39%	46.32%
FREE CASH FLOW
Cash From Operating Activities	-$9.970M	-$115.1M	-$50.27M
Capital Expenditures	-$17.41M	$65.96M	-$14.11M
Free Cash Flow	$7.440M	-$181.1M	-$36.16M
YoY Change	-120.58%	-3.77%	79.37%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020	dei	Amendment Flag AmendmentFlag	false
CY2020	dei	Entity Central Index Key EntityCentralIndexKey	0001737287
CY2020	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2018Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.1905
CY2019Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	allo:AccruedAndOtherLiabilitiesCurrent
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-12-31
CY2020Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	allo:AccruedAndOtherLiabilitiesCurrent
CY2020	dei	Document Type DocumentType	10-K
CY2020	dei	Document Type DocumentType	10-K
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020	dei	Document Transition Report DocumentTransitionReport	false
CY2020	dei	Document Transition Report DocumentTransitionReport	false
CY2020	dei	Entity File Number EntityFileNumber	001-38693
CY2020	dei	Entity File Number EntityFileNumber	001-38693
CY2020	dei	Entity Registrant Name EntityRegistrantName	Allogene Therapeutics, Inc.
CY2020	dei	Entity Registrant Name EntityRegistrantName	Allogene Therapeutics, Inc.
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-3562771
CY2020	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-3562771
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	210 East Grand Avenue
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	South San Francisco
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	210 East Grand Avenue
CY2020	dei	Local Phone Number LocalPhoneNumber	457-2700
CY2020	dei	Local Phone Number LocalPhoneNumber	457-2700
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	South San Francisco
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94080
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94080
CY2020	dei	City Area Code CityAreaCode	650
CY2020	dei	City Area Code CityAreaCode	650
CY2020	dei	Security12b Title Security12bTitle	Common Stock, Par Value $0.001 Per Share
CY2020	dei	Security12b Title Security12bTitle	Common Stock, Par Value $0.001 Per Share
CY2020	dei	Trading Symbol TradingSymbol	ALLO
CY2020	dei	Trading Symbol TradingSymbol	ALLO
CY2020	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2020	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2020	dei	Entity Small Business EntitySmallBusiness	false
CY2020	dei	Entity Small Business EntitySmallBusiness	false
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Public Float EntityPublicFloat	3509000000	USD
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	140647818	shares
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	183351000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	175126000	USD
CY2020Q4	us-gaap	Short Term Investments ShortTermInvestments	644559000	USD
CY2019Q4	us-gaap	Short Term Investments ShortTermInvestments	355407000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	17220000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	14043000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	845130000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	544576000	USD
CY2020Q4	us-gaap	Other Long Term Investments OtherLongTermInvestments	204208000	USD
CY2019Q4	us-gaap	Other Long Term Investments OtherLongTermInvestments	58322000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	41295000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	44495000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	118840000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	56449000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	0	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	151000	USD
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	9449000	USD
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	4299000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5169000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4618000	USD
CY2020Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	3738000	USD
CY2019Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	4892000	USD
CY2020Q4	us-gaap	Assets Assets	1227829000	USD
CY2019Q4	us-gaap	Assets Assets	717802000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10390000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9250000	USD
CY2020Q4	allo	Accrued And Other Liabilities Current AccruedAndOtherLiabilitiesCurrent	44938000	USD
CY2019Q4	allo	Accrued And Other Liabilities Current AccruedAndOtherLiabilitiesCurrent	23829000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	38992000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	94320000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	33079000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	50809000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	51349000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3083000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4351000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	148212000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	88779000	USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	140474305	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	140474305	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	124267358	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	124267358	shares
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	140000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	124000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1725552000	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1023876000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-646343000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-396122000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	268000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1145000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1079617000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	629023000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1227829000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	717802000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	192987000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	144535000	USD
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	151860000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	65256000	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	57473000	USD
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	40982000	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	258243000	USD
CY2019	us-gaap	Operating Expenses OperatingExpenses	202008000	USD
CY2018	us-gaap	Operating Expenses OperatingExpenses	192842000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-258243000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-202008000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-192842000	USD
CY2020	allo	Change In Fair Value Of Convertible Note Payable ChangeInFairValueOfConvertibleNotePayable	0	USD
CY2019	allo	Change In Fair Value Of Convertible Note Payable ChangeInFairValueOfConvertibleNotePayable	0	USD
CY2018	allo	Change In Fair Value Of Convertible Note Payable ChangeInFairValueOfConvertibleNotePayable	21211000	USD
CY2020	us-gaap	Interest Expense InterestExpense	0	USD
CY2019	us-gaap	Interest Expense InterestExpense	0	USD
CY2018	us-gaap	Interest Expense InterestExpense	3358000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	9164000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	17351000	USD
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5789000	USD
CY2020	us-gaap	Other Expenses OtherExpenses	1142000	USD
CY2019	us-gaap	Other Expenses OtherExpenses	268000	USD
CY2018	us-gaap	Other Expenses OtherExpenses	0	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	8022000	USD
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	17083000	USD
CY2018	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-18780000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-250221000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-184925000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-211622000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-331000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-117000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-250221000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-184594000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	839000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-211505000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-877000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	306000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-251098000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-183755000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-211199000	USD
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.08
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.83
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-7.31
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	120370177	shares
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	101061149	shares
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	28948386	shares
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	-2000	USD
CY2018	allo	Stock Issued During Period Value Common Stock Issues StockIssuedDuringPeriodValueCommonStockIssues	5000	USD
CY2018	allo	Subscriptions Receivable From Preferred Stockholders SubscriptionsReceivableFromPreferredStockholders	150000000	USD
CY2018	allo	Stock Issued During Period Value Preferred Stock Issues StockIssuedDuringPeriodValuePreferredStockIssues	150000000	USD
CY2018	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5000	USD
CY2018	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	411052000	USD
CY2018	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	141410000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Stock Split AdjustmentsToAdditionalPaidInCapitalStockSplit	2000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	18566000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-211505000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	306000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	703164000	USD
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2959000	USD
CY2019	allo	Stock Issued During Period Value Vesting Of Early Exercised Stock Options StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions	4590000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	46063000	USD
CY2019	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1783000	USD
CY2019	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	54219000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-184594000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	839000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	629023000	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	8815000	USD
CY2020	allo	Stock Issued During Period Value Vesting Of Early Exercised Stock Options StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions	2840000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	65261000	USD
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2843000	USD
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	595730000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-250221000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-877000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1079617000	USD
CY2020	us-gaap	Profit Loss ProfitLoss	-250221000	USD
CY2019	us-gaap	Profit Loss ProfitLoss	-184594000	USD
CY2018	us-gaap	Profit Loss ProfitLoss	-211505000	USD
CY2020	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2019	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2018	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	109436000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	65261000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	46063000	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	18566000	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	151000	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	603000	USD
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	452000	USD
CY2020	us-gaap	Depreciation Depreciation	7435000	USD
CY2019	us-gaap	Depreciation Depreciation	4424000	USD
CY2018	us-gaap	Depreciation Depreciation	1048000	USD
CY2020	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-3250000	USD
CY2019	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	3596000	USD
CY2018	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	1036000	USD
CY2020	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	3955000	USD
CY2019	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	6777000	USD
CY2018	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1832000	USD
CY2020	allo	Change In Fair Value Of Convertible Note Payable ChangeInFairValueOfConvertibleNotePayable	0	USD
CY2019	allo	Change In Fair Value Of Convertible Note Payable ChangeInFairValueOfConvertibleNotePayable	0	USD
CY2018	allo	Change In Fair Value Of Convertible Note Payable ChangeInFairValueOfConvertibleNotePayable	21211000	USD
CY2020	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	USD
CY2019	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	USD
CY2018	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	3358000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-331000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-117000	USD
CY2020	allo	Income Loss From Cost Method Investment IncomeLossFromCostMethodInvestment	-1154000	USD
CY2019	allo	Income Loss From Cost Method Investment IncomeLossFromCostMethodInvestment	-182000	USD
CY2018	allo	Income Loss From Cost Method Investment IncomeLossFromCostMethodInvestment	0	USD
CY2020	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	0	USD
CY2019	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	0	USD
CY2018	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	6000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3177000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	5445000	USD
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	8598000	USD
CY2020	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-34000	USD
CY2019	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	4374000	USD
CY2018	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	244000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	615000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-985000	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	8800000	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	18726000	USD
CY2019	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	6351000	USD
CY2018	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	12138000	USD
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	38992000	USD
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	USD
CY2018	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	USD
CY2020	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-1268000	USD
CY2019	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-2425000	USD
CY2018	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	0	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-115093000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-137350000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-44653000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	65958000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	50791000	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3234000	USD
CY2020	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	0	USD
CY2019	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	5075000	USD
CY2018	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	0	USD
CY2020	us-gaap	Proceeds From Sale Of Other Investments ProceedsFromSaleOfOtherInvestments	4799000	USD
CY2019	us-gaap	Proceeds From Sale Of Other Investments ProceedsFromSaleOfOtherInvestments	0	USD
CY2018	us-gaap	Proceeds From Sale Of Other Investments ProceedsFromSaleOfOtherInvestments	2606000	USD
CY2020	us-gaap	Proceeds From Maturities Prepayments And Calls Of Other Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments	593627000	USD
CY2019	us-gaap	Proceeds From Maturities Prepayments And Calls Of Other Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments	472578000	USD
CY2018	us-gaap	Proceeds From Maturities Prepayments And Calls Of Other Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments	19235000	USD
CY2020	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	1037591000	USD
CY2019	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	252628000	USD
CY2018	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	649307000	USD
CY2020	us-gaap	Payments To Acquire Assets Investing Activities PaymentsToAcquireAssetsInvestingActivities	0	USD
CY2019	us-gaap	Payments To Acquire Assets Investing Activities PaymentsToAcquireAssetsInvestingActivities	0	USD
CY2018	us-gaap	Payments To Acquire Assets Investing Activities PaymentsToAcquireAssetsInvestingActivities	2098000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-505123000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	164084000	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-632798000	USD
CY2020	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0	USD
CY2019	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0	USD
CY2018	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	299281000	USD
CY2020	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2019	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2018	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	116842000	USD
CY2020	allo	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Early Exercise Of Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfStockOptions	0	USD
CY2019	allo	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Early Exercise Of Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfStockOptions	0	USD
CY2018	allo	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Early Exercise Of Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfStockOptions	11370000	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	621933000	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	54219000	USD
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	343689000	USD
CY2020	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	8815000	USD
CY2019	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	2958000	USD
CY2018	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	0	USD
CY2020	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	2843000	USD
CY2019	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1783000	USD
CY2018	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	0	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	633591000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	58960000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	771182000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	13375000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	85694000	USD
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	93731000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	179425000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	93731000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	192800000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	179425000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	93731000	USD
CY2020	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	0	USD
CY2019	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	0	USD
CY2018	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	411052000	USD
CY2020	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2018	allo	Property Plant Equipment And Other Assets Acquired In Asset Acquisition PropertyPlantEquipmentAndOtherAssetsAcquiredInAssetAcquisition	111770000	USD
CY2019	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2018	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	141410000	USD
CY2020	allo	Convertible Preferred Stock Issued In Asset Acquisition ConvertiblePreferredStockIssuedInAssetAcquisition	0	USD
CY2019	allo	Convertible Preferred Stock Issued In Asset Acquisition ConvertiblePreferredStockIssuedInAssetAcquisition	0	USD
CY2018	allo	Convertible Preferred Stock Issued In Asset Acquisition ConvertiblePreferredStockIssuedInAssetAcquisition	111770000	USD
CY2020	allo	Property Plant Equipment And Other Assets Acquired In Asset Acquisition PropertyPlantEquipmentAndOtherAssetsAcquiredInAssetAcquisition	0	USD
CY2019	allo	Property Plant Equipment And Other Assets Acquired In Asset Acquisition PropertyPlantEquipmentAndOtherAssetsAcquiredInAssetAcquisition	0	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	13827000	USD
CY2018	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	33015000	USD
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	8567000	USD
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	4668000	USD
CY2018	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	3182000	USD
CY2020	allo	Capitalized Costs CapitalizedCosts	584000	USD
CY2019	allo	Capitalized Costs CapitalizedCosts	0	USD
CY2018	allo	Capitalized Costs CapitalizedCosts	0	USD
CY2020	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	USD
CY2019	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	135000	USD
CY2018	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	356000	USD
CY2020	us-gaap	Payments For Leasing Costs Commissions And Tenant Improvements PaymentsForLeasingCostsCommissionsAndTenantImprovements	6244000	USD
CY2019	us-gaap	Payments For Leasing Costs Commissions And Tenant Improvements PaymentsForLeasingCostsCommissionsAndTenantImprovements	3563000	USD
CY2018	us-gaap	Payments For Leasing Costs Commissions And Tenant Improvements PaymentsForLeasingCostsCommissionsAndTenantImprovements	31000	USD
CY2020	us-gaap	Payments For Proceeds From Tenant Allowance PaymentsForProceedsFromTenantAllowance	-2809000	USD
CY2019	us-gaap	Payments For Proceeds From Tenant Allowance PaymentsForProceedsFromTenantAllowance	-4473000	USD
CY2018	us-gaap	Payments For Proceeds From Tenant Allowance PaymentsForProceedsFromTenantAllowance	0	USD
CY2017Q4	allo	Start Up Cost StartUpCost	2000	USD
CY2019Q4	allo	Stock Issuance Maximum Value StockIssuanceMaximumValue	250000000.0	USD
CY2019Q4	allo	Stock Issuance Maximum Compensation Due To Third Party Percent StockIssuanceMaximumCompensationDueToThirdPartyPercent	0.030
CY2020Q2	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	13457447	shares
CY2020Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	47.00
CY2020Q2	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	632500000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	595700000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	1000000000.0	USD
	us-gaap	Net Income Loss NetIncomeLoss	-646300000	USD
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying consolidated financial statements include but are not limited to the fair value of common stock, the fair value of stock options, the fair value of investments, the fair value of convertible notes payable upon conversion, income tax uncertainties, and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances change. Actual results could differ from those estimates.</span></div>
CY2020	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit and other Risks and Uncertainties</span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and investments. The primary objectives for the Company’s investment portfolio are the preservation of capital and the maintenance of liquidity. The Company does not enter into any investment transaction for trading or speculative purposes.</span></div><div style="margin-top:12pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s investment policy limits investments to certain types of instruments such as certificates of deposit, commercial paper, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company maintains cash balances in excess of amounts insured by the FDIC and concentrated within a limited number of financial institutions. The accounts are monitored by management and management believes that the financial institutions are financially sound, and, accordingly, minimal credit risk exists with respect to these financial institutions. As of December 31, 2020 and 2019, the Company has not experienced any credit losses in such accounts or investments.</span></div><div style="margin-top:12pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to a number of risks common for early-stage biopharmaceutical companies including, but not limited to, dependency on the clinical and commercial success of its product candidates, ability to obtain regulatory approval of its product candidates, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and patients, significant competition and untested manufacturing capabilities.</span></div>
CY2020	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2019Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	122900000	USD
CY2020	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P2Y
CY2020	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	0	USD
CY2019	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	200000	USD
CY2020Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	4200000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	950095000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	764000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	53000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	950806000	USD
CY2020Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	102039000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	644559000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	204208000	USD
CY2020Q4	allo	Cash Equivalents And Short Term Investments CashEquivalentsAndShortTermInvestments	950806000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	535042000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1595000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	8000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	536629000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Term DebtSecuritiesAvailableForSaleTerm	P3Y
CY2020Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	644559000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	355407000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	58322000	USD
CY2019Q4	allo	Cash Equivalents And Short Term Investments CashEquivalentsAndShortTermInvestments	536629000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	355407000	USD
CY2020Q4	allo	Available For Sale Securities Debt Maturities After One Through Two Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue	148211000	USD
CY2019Q4	allo	Available For Sale Securities Debt Maturities After One Through Two Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue	58322000	USD
CY2020Q4	allo	Available For Sale Securities Debt Maturities Within Three Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinThreeYearFairValue	55997000	USD
CY2019Q4	allo	Available For Sale Securities Debt Maturities Within Three Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinThreeYearFairValue	0	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Maturities Without Single Maturity Date Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue	102039000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Maturities Without Single Maturity Date Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue	122900000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	950806000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	536629000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Term DebtSecuritiesAvailableForSaleTerm	P2Y
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	7400000	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4600000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	5000000.0	USD
CY2018	us-gaap	Other Than Temporary Impairment Losses Investments Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities	0	USD
CY2020	us-gaap	Other Than Temporary Impairment Losses Investments Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities	0	USD
CY2019	us-gaap	Other Than Temporary Impairment Losses Investments Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities	0	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	0	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss	2800000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss	2400000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	131748000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	61921000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	12908000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5472000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	118840000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	56449000	USD
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1000000.0	USD
CY2020	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	0	USD
CY2019	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	200000	USD
CY2018	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	0	USD
CY2020Q4	allo	Accrued Compensation And Related Benefits Current AccruedCompensationAndRelatedBenefitsCurrent	15943000	USD
CY2019Q4	allo	Accrued Compensation And Related Benefits Current AccruedCompensationAndRelatedBenefitsCurrent	9560000	USD
CY2020Q4	allo	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	13887000	USD
CY2019Q4	allo	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	4833000	USD
CY2020Q4	allo	Accrued Property And Equipment AccruedPropertyAndEquipment	7475000	USD
CY2019Q4	allo	Accrued Property And Equipment AccruedPropertyAndEquipment	3575000	USD
CY2020Q4	allo	Unvested Shares Liabilities Current UnvestedSharesLiabilitiesCurrent	2842000	USD
CY2019Q4	allo	Unvested Shares Liabilities Current UnvestedSharesLiabilitiesCurrent	2843000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	4791000	USD
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3018000	USD
CY2020Q4	allo	Accrued And Other Liabilities Current AccruedAndOtherLiabilitiesCurrent	44938000	USD
CY2019Q4	allo	Accrued And Other Liabilities Current AccruedAndOtherLiabilitiesCurrent	23829000	USD
CY2018Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment	3258000	USD
CY2018Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets	113900000	USD
CY2018Q2	allo	Discount Rate For Valuation DiscountRateForValuation	0.165
CY2020Q4	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	5200000	USD
CY2019Q4	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	4300000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2974000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1679000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	50809000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	51349000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	53783000	USD
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	53028000	USD
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	7390000	USD
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	5945000	USD
CY2018	us-gaap	Operating Lease Cost OperatingLeaseCost	1863000	USD
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	1382000	USD
CY2019	us-gaap	Variable Lease Cost VariableLeaseCost	1087000	USD
CY2018	us-gaap	Variable Lease Cost VariableLeaseCost	32000	USD
CY2020	us-gaap	Lease Cost LeaseCost	8771000	USD
CY2019	us-gaap	Lease Cost LeaseCost	7033000	USD
CY2018	us-gaap	Lease Cost LeaseCost	1895000	USD
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	6200000	USD
CY2020Q4	us-gaap	Asset Retirement Obligation AssetRetirementObligation	500000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	6485000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	7917000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	8168000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	8430000	USD
CY2020Q4	allo	Lessee Operating Lease Liability Payments Due Year Five And After Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive	56654000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	87653000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	32313000	USD
CY2020Q4	allo	Allowance For Tenant Improvements AllowanceForTenantImprovements	1557000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	53783000	USD
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0837
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P10Y3M10D
CY2020	allo	Shortterm Lease Rent Expense ShorttermLeaseRentExpense	200000	USD
CY2019	allo	Shortterm Lease Rent Expense ShorttermLeaseRentExpense	2400000	USD
CY2018	allo	Shortterm Lease Rent Expense ShorttermLeaseRentExpense	2600000	USD
CY2018Q3	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	120200000	USD
CY2019Q4	us-gaap	Asset Retirement Obligation AssetRetirementObligation	400000	USD
CY2020Q4	us-gaap	Purchase Commitment Remaining Minimum Amount Committed PurchaseCommitmentRemainingMinimumAmountCommitted	5400000	USD
CY2018Q3	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	116800000	USD
CY2018Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	120200000	USD
CY2018Q4	us-gaap	Debt Conversion Converted Instrument Rate DebtConversionConvertedInstrumentRate	0.85
CY2018Q4	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	141400000	USD
CY2020	us-gaap	Increase Decrease In Notes Payable Current IncreaseDecreaseInNotesPayableCurrent	0	USD
CY2019	us-gaap	Increase Decrease In Notes Payable Current IncreaseDecreaseInNotesPayableCurrent	21200000	USD
CY2020Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	3400000	USD
CY2018Q2	allo	Aggregate Purchase Price Shares Value AggregatePurchasePriceSharesValue	300000000.0	USD
CY2018Q3	us-gaap	Temporary Equity Shares Subscribed But Unissued Subscriptions Receivable TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable	150000000.0	USD
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	140474305	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	140474305	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	124267358	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	124267358	shares
CY2020	allo	Modification Of Convertible Preferred Stock For Common Stock ModificationOfConvertiblePreferredStockForCommonStock	26249993	shares
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost	59500000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2020	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0
CY2019	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0
CY2020	allo	Number Of Shares As Percentage Of Common Shares Outstanding NumberOfSharesAsPercentageOfCommonSharesOutstanding	0.05
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	93149000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	65261000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	46063000	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	18566000	USD
CY2020Q4	us-gaap	Deferred Compensation Share Based Arrangements Liability Current DeferredCompensationShareBasedArrangementsLiabilityCurrent	2800000	USD
CY2019Q4	us-gaap	Deferred Compensation Share Based Arrangements Liability Current DeferredCompensationShareBasedArrangementsLiabilityCurrent	2800000	USD
CY2020	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	1400000	USD
CY2019	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	900000	USD
CY2018	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	400000	USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2018	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1000	USD
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	2000	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1000	USD
CY2018	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	2000	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-251000	USD
CY2018	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-89000	USD
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2018	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-30000	USD
CY2020	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-81000	USD
CY2019	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	-332000	USD
CY2018	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	-119000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-331000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-117000	USD
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-52546000	USD
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-38834000	USD
CY2018	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-44441000	USD
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-18656000	USD
CY2019	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-12951000	USD
CY2018	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-10652000	USD
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	997000	USD
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	2037000	USD
CY2018	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	3629000	USD
CY2020	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	2319000	USD
CY2019	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	1714000	USD
CY2018	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	708000	USD
CY2020	allo	Income Tax Reconciliation Write Off Of In Process Research And Development IncomeTaxReconciliationWriteOffOfInProcessResearchAndDevelopment	0	USD
CY2019	allo	Income Tax Reconciliation Write Off Of In Process Research And Development IncomeTaxReconciliationWriteOffOfInProcessResearchAndDevelopment	0	USD
CY2018	allo	Income Tax Reconciliation Write Off Of In Process Research And Development IncomeTaxReconciliationWriteOffOfInProcessResearchAndDevelopment	5247000	USD
CY2020	allo	Income Tax Reconciliation Change In Fair Value Of Convertible Notes IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes	0	USD
CY2019	allo	Income Tax Reconciliation Change In Fair Value Of Convertible Notes IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes	0	USD
CY2018	allo	Income Tax Reconciliation Change In Fair Value Of Convertible Notes IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes	4454000	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	72538000	USD
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	49989000	USD
CY2018	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	41916000	USD
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-14000	USD
CY2019	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	1142000	USD
CY2018	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	438000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-117000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	8297000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-331000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	115199000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	54018000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	16437000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	4239000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	1239000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	20582000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	22770000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	23086000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	3888000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	2375000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	952000	USD
CY2020Q4	allo	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	15050000	USD
CY2019Q4	allo	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	14839000	USD
CY2018Q4	allo	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	9730000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	12970000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	6870000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	360000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Investments DeferredTaxAssetsInvestments	175000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Investments DeferredTaxAssetsInvestments	0	USD
CY2018Q4	us-gaap	Deferred Tax Assets Investments DeferredTaxAssetsInvestments	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	12000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	0	USD
CY2018Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	176173000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	105111000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	51804000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	172000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	361000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	531000	USD
CY2020Q4	allo	Deferred Tax Liabilities Right Of Use Leased DeferredTaxLiabilitiesRightOfUseLeased	11556000	USD
CY2019Q4	allo	Deferred Tax Liabilities Right Of Use Leased DeferredTaxLiabilitiesRightOfUseLeased	12453000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Investments DeferredTaxLiabilitiesInvestments	118000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0	USD
CY2018Q4	allo	Deferred Tax Liabilities Right Of Use Leased DeferredTaxLiabilitiesRightOfUseLeased	9239000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Investments DeferredTaxLiabilitiesInvestments	0	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Investments DeferredTaxLiabilitiesInvestments	393000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	11728000	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	13207000	USD
CY2018Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	9888000	USD
CY2020Q4	allo	Deferred Tax Assets Net Of Deferred Tax Liabilities DeferredTaxAssetsNetOfDeferredTaxLiabilities	164445000	USD
CY2019Q4	allo	Deferred Tax Assets Net Of Deferred Tax Liabilities DeferredTaxAssetsNetOfDeferredTaxLiabilities	91904000	USD
CY2018Q4	allo	Deferred Tax Assets Net Of Deferred Tax Liabilities DeferredTaxAssetsNetOfDeferredTaxLiabilities	41916000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	164445000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	91904000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	41916000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2018Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2020	us-gaap	Valuation Allowances And Reserves Period Increase Decrease ValuationAllowancesAndReservesPeriodIncreaseDecrease	72500000	USD
CY2019	us-gaap	Valuation Allowances And Reserves Period Increase Decrease ValuationAllowancesAndReservesPeriodIncreaseDecrease	50000000.0	USD
CY2018	us-gaap	Valuation Allowances And Reserves Period Increase Decrease ValuationAllowancesAndReservesPeriodIncreaseDecrease	41900000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	300000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	100000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3148000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	920000	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	2228000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	920000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2018	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	3013000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	USD
CY2018	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6161000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3148000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	920000	USD
CY2018Q4	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	0	USD
CY2019Q4	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	0	USD
CY2020Q4	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	0	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-250221000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-184594000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-211505000	USD
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	120370177	shares
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	101061149	shares
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	28948386	shares
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.08
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.83
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-7.31
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	22549960	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	27948931	shares
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	32087884	shares

Files In Submission

Name	View Source	Status
0001737287-21-000009-index-headers.html	Edgar Link	pending
0001737287-21-000009-index.html	Edgar Link	pending
0001737287-21-000009.txt	Edgar Link	pending
0001737287-21-000009-xbrl.zip	Edgar Link	pending
allo-20201231.htm	Edgar Link	pending
allo-20201231.xsd	Edgar Link	pending
allo-20201231xex1024.htm	Edgar Link	pending
allo-20201231xex1025.htm	Edgar Link	pending
allo-20201231xex231.htm	Edgar Link	pending
allo-20201231xex311.htm	Edgar Link	pending
allo-20201231xex312.htm	Edgar Link	pending
allo-20201231xex321.htm	Edgar Link	pending
allo-20201231xex322.htm	Edgar Link	pending
allo-20201231_cal.xml	Edgar Link	unprocessable
allo-20201231_def.xml	Edgar Link	unprocessable
allo-20201231_g1.jpg	Edgar Link	pending
allo-20201231_g10.jpg	Edgar Link	pending
allo-20201231_g11.jpg	Edgar Link	pending
allo-20201231_g12.jpg	Edgar Link	pending
allo-20201231_g2.jpg	Edgar Link	pending
allo-20201231_g3.jpg	Edgar Link	pending
allo-20201231_g4.jpg	Edgar Link	pending
allo-20201231_g5.jpg	Edgar Link	pending
allo-20201231_g6.jpg	Edgar Link	pending
allo-20201231_g7.jpg	Edgar Link	pending
allo-20201231_g8.jpg	Edgar Link	pending
allo-20201231_g9.jpg	Edgar Link	pending
allo-20201231_htm.xml	Edgar Link	completed
allo-20201231_lab.xml	Edgar Link	unprocessable
allo-20201231_pre.xml	Edgar Link	unprocessable
allo-2020x1231xex1023.htm	Edgar Link	pending
allo-2020x1231xex107.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ALLO
Allogene Therapeutics, Inc. Stock $allo

2020 Q4 Form 10-K Financial Statement

#000173728721000009 Filed on February 25, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALLO Allogene Therapeutics, Inc. Stock $allo

2020 Q4 Form 10-K Financial Statement

#000173728721000009 Filed on February 25, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALLO
Allogene Therapeutics, Inc. Stock $allo